QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Expected outcomes of therapy
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

1 evidence topic · 1 source

SELVA: observed mLM-IGA improvement among efficacy-period completers aged at least 6 years

“95% (41/43) demonstrated at least a 1-point improvement” (opens the source at this quote in a new tab)